Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

After 20 years and $200 billion in revenue, Humira — an injectable treatment for rheumatoid arthritis and several other autoimmune conditions — has lost its monopoly. Early Tuesday morning, California ...

Optum Rx will add two more Humira biosimilars to its formulary later this summer. The pharmacy benefit manager—one of the three largest in the market—will place Boehringer Ingelheim's Cyltezo and ...

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July. But lower pharmacy ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2021, Humira — the blockbuster biologic that has for ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Patients who take the autoimmune disease ...